StreetInsider.com News Articles

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Mon, 19 Oct 2026 09:53:00 -0400

Live Presentation and Q&A: Tuesday, October 20, 2026 12 PM EDT

King of Prussia, Pennsylvania--(Newsfile Corp. - October 19, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL^® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL^® siRNA therapeutic platform, including its lead clinical candidate PH-762 for the treatment of cutaneous carcinomas. The presentation will be followed by a live Q&A session.

"We look forward to engaging with investors at the Renmark Financial Virtual

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Mon, 19 Oct 2026 09:53:00 -0400

Live Presentation and Q&A: Tuesday, October 20, 2026 12 PM EDT

"We look forward to engaging with investors at the Renmark Financial Virtual

Form 8-K Phio Pharmaceuticals For: Oct 13

Tue, 13 Oct 2026 08:42:00 -0400

si-local-file:///var/storage/secattach/20261013/27177970.html

Phio Pharma completes first commercial-scale cGMP batch of PH-762

Tue, 13 Oct 2026 07:05:07 -0400

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) announced the successful release of its first commercial-scale current Good Manufacturing Practice (cGMP) batch of PH-762 drug substance, according to a company statement.

The batch was manufactured in compliance with cGMP regulations, the approved Master Batch Record, and ICH Q7 guidelines, and was confirmed by a Certificate of Analysis and Certificate of Compliance.

The drug substance will proceed through final drug product completion steps for use in a planned Phase 2b clinical study, which the company expects to initiate in the first quarter of 2027.

PH-762 is an siRNA compound that targets the PD-1 gene and is being

Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance

Tue, 13 Oct 2026 07:00:00 -0400

Critical Manufacturing Milestone Supports Supply Chain Readiness and Planned Phase 2b Clinical Trial Initiation in First Quarter 2027

King of Prussia, Pennsylvania--(Newsfile Corp. - October 13, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary INTASYL® siRNA gene-silencing platform, today announced the successful release of its first commercial-scale cGMP batch of PH-762 drug substance (active pharmaceutical ingredient), representing a critical operational and strategic milestone as the Company advances PH-762 to the next stage of clinical development.

The batch was manufactured in accordance with established specifications and quality requirements, as confirmed by the

Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance

Tue, 13 Oct 2026 07:00:00 -0400

Critical Manufacturing Milestone Supports Supply Chain Readiness and Planned Phase 2b Clinical Trial Initiation in First Quarter 2027

The batch was manufactured in accordance with established specifications and quality requirements, as confirmed by the

OTC Markets Group Announces Third Annual Global Markets Forum Presentations Now Available On Demand

Mon, 12 Oct 2026 08:35:00 -0400

View presentations from European and Canadian public growth companies following the October 7–8 event

NEW YORK, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that presentations from the third annual Global Markets Forum, held October 7–8, 2026, are now available for on-demand viewing. The event was presented in partnership with Aquis Stock Exchange, BME, Canadian Securities Exchange (CSE), OTC Markets Group, and SIX Swiss Exchange.

The two-day event brought together C-suite executives from leading European and Canadian public growth companies to share insights into their businesses, growth strategies, and

OTC Markets Group Announces Third Annual Global Markets Forum Presentations Now Available On Demand

Mon, 12 Oct 2026 08:35:00 -0400

View presentations from European and Canadian public growth companies following the October 7–8 event

The two-day event brought together C-suite executives from leading European and Canadian public growth companies to share insights into their businesses, growth strategies, and

OTC Markets Group Announces Third Annual Global Markets Forum Presentations Now Available On Demand

Mon, 12 Oct 2026 08:35:00 -0400

View presentations from European and Canadian public growth companies following the October 7–8 event

The two-day event brought together C-suite executives from leading European and Canadian public growth companies to share insights into their businesses, growth strategies, and

OTC Markets Group Announces Third Annual Global Markets Forum Presentations Now Available On Demand

Mon, 12 Oct 2026 08:35:00 -0400

View presentations from European and Canadian public growth companies following the October 7–8 event

The two-day event brought together C-suite executives from leading European and Canadian public growth companies to share insights into their businesses, growth strategies, and

OTC Markets Group Announces Third Annual Global Markets Forum Presentations Now Available On Demand

Mon, 12 Oct 2026 08:35:00 -0400

View presentations from European and Canadian public growth companies following the October 7–8 event

The two-day event brought together C-suite executives from leading European and Canadian public growth companies to share insights into their businesses, growth strategies, and

OTC Markets Group Announces Third Annual Global Markets Forum Presentations Now Available On Demand

Mon, 12 Oct 2026 08:35:00 -0400

View presentations from European and Canadian public growth companies following the October 7–8 event

The two-day event brought together C-suite executives from leading European and Canadian public growth companies to share insights into their businesses, growth strategies, and

Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026

Tue, 06 Oct 2026 07:00:00 -0400

Phio invites individual and institutional investors as well as advisors and analysts, to attend online at www.VirtualInvestorConference.com

King of Prussia, Pennsylvania--(Newsfile Corp. - October 6, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary INTASYL® siRNA gene-silencing platform, today announced that Robert Bitterman, President and Chief Executive Officer, will present Phio's INTASYL® siRNA therapeutic platform, its differentiated delivery approach, and the Company's strategic direction at The Global Markets Virtual Forum hosted by www.VirtualInvestorConferences.com (VIC) on October 8^th, 2026.

"The Global Markets Virtual Forum offers a unique forum to highlight Phio's differentiated siRNA

Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026

Tue, 06 Oct 2026 07:00:00 -0400

Phio invites individual and institutional investors as well as advisors and analysts, to attend online at www.VirtualInvestorConference.com

"The Global Markets Virtual Forum offers a unique forum to highlight Phio's differentiated siRNA

OTC Markets Group Announces Agenda for Third Annual Global Markets Forum, October 7th & 8th